New Experimental Drug Outperforms Standard Therapy in Advanc
Their findings, published in the Journal of Clinical Oncology, showed that people who received the experimental drug cabozantinib had a longer time before their cancer worsened than those taking sunitinib (Sutent), which is considered to be the initial drug treatment for metastatic kidney cancer for the last 10 years....

http://www.natureworldnews.com/articles/32052/20161116/new-experimental-drug-outperforms-standard-therapy-advanced-kidney-cancer.htm
Like
Comment
Share